ProfileGDS5678 / 1445228_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 55% 55% 55% 55% 53% 56% 55% 54% 55% 54% 55% 55% 55% 55% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.4360155
GSM967853U87-EV human glioblastoma xenograft - Control 23.373955
GSM967854U87-EV human glioblastoma xenograft - Control 33.3590955
GSM967855U87-EV human glioblastoma xenograft - Control 43.3218355
GSM967856U87-EV human glioblastoma xenograft - Control 53.2668453
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.5263256
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.4807255
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.3461154
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.3405455
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.3230554
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.3659555
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.3469955
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.3736655
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.3640155